North Carolina has already has already had substantial numbers of women and children detected with HIV disease. Several features of the HIV/AIDS epidemic predict a rapidly increasing problem with HIV disease in women and children: e.g., the percentages of reported AIDS cases in women and minorities are higher than the national averages and are growing, and the proportions of cases associated with IV drug use or heterosexual transmission are also disproportionately high. Also, epidemiologic data in our state suggest that about one-fourth of our AIDS causes may be associated with risk behaviors adopted during adolescence. Current ACTG data indicate that our pediatric component is one of the top enrollers of adolescents in ACTG trials; and it is in the top quarter of pediatric components of adult ACTUs, in total enrollment of children/adolescents into ACTG trials. Three areas of clinical focus have evolved: (a) provision of comprehensive services to referred HIV-exposed infants and their mothers; (2) optimal care for the many HIV-infected hemophiliacs in our Comprehensive Hemophilia Center, one of the nation's largest; and (3) establishment of a statewide adolescent outreach program, to provide HIV educational, preventive, and medical-referral services to HIV at-risk adolescents in our state. The primary goal of our pediatric component is provision of coordinated, state-of-the-art, comprehensive clinical care to these patient populations, in conjunction with their enrollment into ACTG studies. Ongoing clinical and basic research efforts are described herein. Support is requested for the clinical and ancillary services utilized in associated with ACTG activities.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Thio, Chloe L; Smeaton, Laura; Hollabaugh, Kimberly et al. (2015) Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS 29:1173-82
Smith, Kimberly Y; Tierney, Camlin; Mollan, Katie et al. (2014) Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis 58:555-63
Kempen, John H; Sugar, Elizabeth A; Varma, Rohit et al. (2014) Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections. Ophthalmology 121:2317-24
Kozak, Igor; Vaidya, Vijay; Van Natta, Mark L et al. (2014) The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis. Invest Ophthalmol Vis Sci 55:4304-12
Venuto, Charles S; Mollan, Katie; Ma, Qing et al. (2014) Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother 69:3300-10

Showing the most recent 10 out of 174 publications